Mental Health Blogs

Alexza Pharmaceuticals announced today that it’s submitted a new drug application for Staccato loxapine (AZ-004). It’s an inhalant designed to be used to address cases of agitation in schizophrenia and bipolar disorder. Much of that agitation is often caused by other active treatments patients may be taking (anti-depressants, anti-seizure drugs, antipsychotics), so it does seem a bit wild that a company has developed a drug to deal with it, but that’s the way it goes in the mental health world.

Loxapine itself is a typical antipsychotic that is so seldom used that I’ve never heard of it before now.

Go to Source

Related posts:

1. Reasons To Be Skeptical Of "Female Viagra" Drug, Big Pharma’s Spanish Fly
2. Study: Paxil Is Worst Drug For Suicide Attempts
3. The Anti-Depressant Trap Leads To Bipolar Disorder Diagnosis, Lithium Toxicity
4. Shire Trialing ADHD Drug As Add-On Depression Treatment
5. Anti-Depressants, Antipsychotics Worst Drugs For Falls In Elderly